You are here

Article Text

Article menu
Download PDFPDF
Letters
Methotrexate effect on anti-cyclic citrullinated peptide antibody levels in rheumatoid arthritis
  1. A Spadaro,
  2. V Riccieri
  1. Dip. Clinica e Terapia Medica Applicata-Div, Reumatologia—Università “La Sapienza” Rome, Italy
  1. Correspondence to:
    Professor A Spadaro
    a.spadaro.reumavirgilio.it

https://doi.org/10.1136/ard.2004.032136

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with interest the recent reports1–,3 focusing on the changes of rheumatoid factor and anti-citrullinated peptide antibodies (anti-CCP) during infliximab treatment in refractory rheumatoid arthritis (RA), unresponsive to conventional disease modifying antirheumatic drugs.

    Alessandri et al3 reported that 24 weeks’ infliximab treatment reduced anti-CCP levels according to the study of Bobbio-Pallavicini et al.2 These results are in contrast with the findings of De Rycke et al, which showed no change of this autoantibody serum level after …

    View Full Text